Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross Profit | $97.1M | $150.8M | $204.2M | $185.1M | $159.8M | $87.8M | $130.6M | $1,330.1M | $1,247.2M | $1,081.7M | $519.4M | $906.8M | $1,491.7M | $2,213.5M | $2,638.1M | $3,615.1M | $5,469.4M | $6,670.2M | $7,850.4M | $8,607.0M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Vertex Pharmaceuticals Incorporated's last 12-month Gross Profit is $9,136.4M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Vertex Pharmaceuticals Incorporated's Gross Profit growth was 7.8%. The average annual Gross Profit growth rates for Vertex Pharmaceuticals Incorporated have been 17.4% over the past three years, 23.9% over the past five years.